Investigator Initiated Trial: Ulcerative Proctitis and/or Crohn’s Disease
Immunology
Lilly Immunology is committed to improving the lives of individuals living with immunological diseases and disorders. We are driven to developing innovative solutions through our broad portfolio of therapeutic agents directed at multiple targets in cytokine pathways. Through internal research programs and support of investigator initiated studies, we are dedicated to long-term partnerships that will enable us to make a real impact on individuals’ lives. Lilly is also committed to support external research in Dermatological clinical and molecular aspects affecting patients with skin of color.
We are most likely to support external research in these key areas:
- Research to understand bowel urgency in normal populations v. patients with UC and/or CD
- Ulcerative Proctitis
- Perineal Crohns Disease
- Early Crohns Disease Diagnosis
- Prevention of Post Op recurrence in Crohns Disease
- EIMs (extra–intestinal manifestations) in IBD (UC & CD)
- Combination Therapy Studies
Lilly will not support External Research within its IIR Program in the following areas:
- Any project funded through the Competitive Clinical Research Grants Program (CCRG)
- Studies with a patient population and primary outcome overlapping with planned/ongoing Eli Lilly clinical development program
- Studies with Mirikizumab in the fields of possibly related immunologic or other disease states (e.g., Oncology)
PIRA™ suggested Proposal
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.